MV 014 212
Alternative Names: MV-014-212Latest Information Update: 10 Jul 2024
At a glance
- Originator Meissa Vaccines
- Class Attenuated vaccines; COVID-19 vaccines; Synthetic vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase I COVID 2019 infections
Most Recent Events
- 10 Jul 2024 MV 014 212 is still in phase-I trials for (COVID-2019 infections (Prevention, In adults, In the elderly) in USA (Intranasal, Spray, Drops) (NCT04798001) (Meissa Vaccines pipeline; July 2024)
- 28 May 2024 No recent reports of development identified for phase-I development in COVID-2019-infections(Prevention, In adults, In the elderly) in USA (Intranasal, Drops)
- 28 May 2024 No recent reports of development identified for phase-I development in COVID-2019-infections(Prevention, In adults, In the elderly) in USA (Intranasal, Spray)